Nektar Therapeutics (NKTR) Gross margin 2016–2025
Nektar Therapeutics (NKTR) gross margin by fiscal year — reported gross profit divided by reported revenue.
100.0%FY2025 · since FY2016: 81.7% → 100.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 100.0% | +31.2 pp |
| FY2024 | 68.8% | +6.3 pp |
| FY2023 | 62.5% | -14.0 pp |
| FY2022 | 76.5% | +0.9 pp |
| FY2021 | 75.6% | -11.7 pp |
| FY2020 | 87.3% | +5.9 pp |
| FY2019 | 81.4% | -16.6 pp |
| FY2018 | 98.0% | +7.9 pp |
| FY2017 | 90.1% | +8.3 pp |
| FY2016 | 81.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice